FDC Ltd
NSE: FDC BSE: 531599
₹321.10
(0%)
Thu, 09 Apr 2026, 03:10 am
Market Cap52.29B
PE Ratio24.13
Dividend1.55
Health Technology
Pharmaceuticals: Major
24.5KCompany History
1936
- The Company was promoted as a partnership firm by Late Mr. Anand Chandavarkar.
1940
- The Company was Incorporated as a private limited company.
1949
- A formulation unit was set up at Jogeshwari.
1985
- The name of the Company was changed to FDC Pvt. Ltd.
1988
- The Company was converted into a public limited company.
1991
- A biotechnology based R & D division was set up at Waluj.
- Bulk drugs were formulated into injectables, tablets and capsules at the Jogeshwari Plant.
1993
- The Company commissioned a new unit at Waluj for manufacture of ophthalmic products.
1995
- 72,75,000 equity shares were issued to promoters, directors etc.
- 27,28,200 equity shares were issued at a premium.
- 1,12,400 shares were issued to employees on preferential basis.
- 25,00,800 shares were issued to the public.
1996
- The Company introduced a unique dosage form of ophthalmics.
- A modern biotechnology Lab was set up at Jogeshwari.
- The Company proposed to give a major thrust on computerisation.
- The Company proposed to set up a communication network.
- Fresh capacities were proposed to be built up for bulk drugs.
- The Company undertook to technically upgrade the capacity in the ophthalmic dosages segment.
- The Company undertook to set up two independent units at Sinnar, Nasik.
2000
- The company launched Reliter, a dietary supplement.
2001
- FDC Ltd tied up with Aspen Pharmacre to sell its ophthalmic products in South Africa.
- FDC Ltd launched Simyl MCT Oil, a nutritional supplement.
2002
- Ms Shalini Shenoy was appointed as the Compliance Officer of the company.
2003
- FDC received GMP accreditation from the Medicines Control Council (MCC) of the Republic of South Africa.
- Mr. Rohit R Chandavarkar, the Company's Wholetime Director passed away.
2005
- FDC receives CE mark approval for its 2 products from DNV - Norway.
2009
- Fdc Ltd appointed Mr. Ameya A. Chandavarkar as a whole time director.
2010
- Fdc Limited recommended a dividend of Rs.1.75 per equity share.
2011
- FDC's Ophthalmic facility at Waluj, Aurangabad was approved by UK MHRA.
- FDC received approval for Dorzolamide 2% w/v Eye Drop Solution and Dorzolamide 2% w/v & Timolol Maleate 0.5% w/v Eye Drop Solution from UKMHRA.
- FDC received Certificate of Appreciation Patents award from Pharmexcil.
2012
- FDC Ltd received its first Indian Biotech Patent.
- Fdc Ltd appointed Mr. Vinod G. Yennemadi as an Additional Director.
2013
- Board recommended a Final Dividend of Rs. 2.25 per equity share.
- FDC received IDMA Margi Memorial Best Patent Award.
- FDC received Pharmexcil Patent Award for NEW CHEMICAL ENTITIES (NCEs).
2014
- Board recommended a Final Dividend of Rs. 2.25 per equity share.
- FDC Ltd appointed Ms. Nomita R. Chandavarkar as an Additional Director.
2015
- FDC Ltd purchased a leasehold property situated at Jogeshwari (East).
2016
- FDC to develop cost-effective processes for manufacture of bulk drugs.
- FDC receives two observations from USFDA for Waluj plant.
2020
- FDC Ltd launched two variants of Favipiravir drug for Covid-19.
2022
- FDC Limited's brand Zifi and Favenza were awarded at AWACS 2022.
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800